Loading...
•
Dec 31, 2022
Mink Therapeutics Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year 2022.
Key Takeaways
MiNK Therapeutics reported a net loss of $7.8 million for the fourth quarter of 2022, with a cash balance of $19.6 million at the end of the quarter.
Ended Q4 2022 with a cash balance of $19.6 million.
Cash used in operations for Q4 2022 was $4.4 million.
Net loss for Q4 2022 was $7.8 million, or $0.23 per share.
The increased funding was related to the internalization of our cGMP manufacturing of agenT-797 for clinical trial supply, which has increased our production and will result in decreased supply cost prospectively.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...